FierceBiotech Radio on Valeant feeling the Bern, biotech buckling on Wall Street, and Bristol-Myers turning to Family Feud

FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss how concerns about drug pricing have affected biopharma companies large and small, the latest threat to the biotech bubble, and Bristol-Myers Squibb's interesting televisual choices.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.